查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1861432

蟲媒病毒檢測市場按檢測類型、技術、最終用戶、應用和檢體類型分類－全球預測（2025-2032 年）

Arbovirus Testing Market by Test Type, Technology, End User, Application, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，蟲媒病毒檢測市場將成長至 21 億美元，複合年成長率為 6.02%。

關鍵市場統計數據
基準年 2024 13.1億美元
預計年份：2025年 13.9億美元
預測年份 2032 21億美元
複合年成長率 (%) 6.02%

在媒介動態變化、臨床需求不斷演變和監管要求日益提高的背景下，建構現代化的蟲媒病毒檢測環境

蟲媒病毒持續為全球公共衛生系統、診斷實驗室和監測機構帶來複雜挑戰。快速的國際人口遷移、生態系統變化、都市化和氣候變遷導致病媒分佈和季節性改變，使監測和診斷工作更加複雜。在此背景下，檢測技術正在迅速發展，分子平台、免疫檢測和照護現場等技術各自滿足不同的臨床和操作需求。

診斷領域的相關人員面臨著一個必須兼顧速度、準確性和擴充性與成本和物流的挑戰。實驗室被要求將高通量分子檢測與血清學確診檢測相結合，而臨床醫生則需要快速分流工具來指導病患管理決策。研究機構和製藥公司正在將診斷策略與疫苗和治療藥物的研發相結合，力求建立能夠支持臨床試驗和上市後監測的檢測方法。

此外，日益嚴格的監管預期和品管框架迫使各機構加強對檢驗、品管和互通性的投入。這使得平台選擇、檢體工作流程和供應鏈韌性等策略決策成為診斷規劃的重中之重。本引言旨在透過強調需要技術開發人員、最終使用者和政策制定者共同應對的諸多促進因素，為更深入的分析奠定基礎。

技術創新、數位化連接和靈活的檢測流程推動著蟲媒病毒診斷領域快速發展的前景

在技​​術創新、數位化整合和營運結構重組的驅動下，蟲媒病毒診斷領域正經歷變革性的轉變。即時PCR和數位PCR等分子檢測方法的敏感度和多重檢測能力不斷提升，能夠同時檢測多種病原體，並縮短獲得有效結果的時間。同時，側向層析和其他快速診斷方法也在日趨成熟，其靈敏度更高，操作簡便，更適合分散式環境。

同時，資料整合和互聯互通已成為診斷價值的核心組成部分。實驗室資訊系統和雲端報告正在促進近即時流行病學監測和更協調的公共衛生應對。這種數位化轉型得益於檢測設計方面的進步，包括更精確的抗原標靶和改進的單克隆試劑，從而提高了血清學平台的特異性。

另一個顯著的變化是，人們越來越重視檢體類型的彈性。唾液和尿液等非侵入性檢體基質檢測表現的提升，正在拓展以地區為基礎篩檢和兒科族群的檢測選擇。供應鏈的考量和成本壓力也促使人們更加關注平台整合和模組化工作流程，這些流程能夠靈活地在高通量集中檢測和照護現場之間切換。總而言之，這些變化正在重塑相關人員對診斷作為綜合健康系統應對措施一部分的看法。

評估2025年關稅調整對蟲媒病毒診斷供應鏈籌資策略和業務連續性的累積影響

貿易政策和關稅調整為蟲媒病毒檢測所需的試劑、設備和耗材的採購帶來了新的考量。 2025年關稅調整即時造成了採購的複雜性，迫使各機構重新評估供應商合約、庫存策略和跨境物流，以確保檢測工作的連續性。某些檢測套組組件和設備的額外進口成本也促使各機構更加重視供應鏈在地化和雙重採購安排。

為此，許多實驗室和製造商加快了尋找替代供應商的步伐，並加快評估區域性生產合作可行性的工作。這些措施通常涉及調整採購計劃，以建立關鍵試劑的緩衝庫存，避免限量供應的藥品過時。採購團隊擴大將關稅風險評估納入供應商選擇和合約條款，並就價格保護條款和靈活的交貨時間表進行談判。

此外，受影響地區的監管和海關程序要求與貿易合規專業人員密切合作，以加快關鍵診斷材料的進口核准。對於參與跨國臨床計畫的機構而言，這些關稅變化也促使其加強與申辦者的合作，以確保研究的連續性並防止試劑供應延誤。最終，2025年關稅的累積影響加速了策略轉型，即加強供應鏈韌性，並促進採購、實驗室營運和監管事務部門之間更緊密的合作。

識別測試類型、技術、最終用戶、應用和檢體類型之間的高價值交叉點，這些交叉點決定了診斷的重要性和策略重點。

細分分析揭示了不同檢測類型、技術、最終用戶、應用領域和檢體基質的性能和應用模式的細微差別，從而提供了診斷需求和機會的多面視角。在檢測類型方面，分子檢測、快速診斷檢測和血清學檢測各有側重，它們各自服務於不同的臨床和監測功能，並需要獨特的檢驗途徑和操作流程。在技​​術方面，檢測方法的開發和部署涉及ELISA、橫向流動化驗、微陣列平台和PCR技術的選擇。在ELISA中，競爭法、間接法和夾心法在靈敏度和交叉反應性方面各有優劣，而側向層析設計（競爭法和夾心法）則為照護現場應用提供了不同的性能特徵。微陣列領域包括DNA微陣列和蛋白質微陣列，它們支持高內涵篩檢和病原體發現。 PCR技術包括常規PCR、數位PCR和即時PCR，每種技術都提供不同的分析解析度和通量。在終端使用者層面，診斷需求和採購行為在診斷實驗室、醫院、製藥公司和研究機構之間各不相同。實驗室優先考慮檢測通量和品管，醫院重視快速獲得臨床結果和易用性，製藥公司要求檢測方法標準化，而研究機構則專注於創新和發現能力。按應用領域分類，檢測方法應用於臨床診斷、流行病學監測、研究和獸醫檢測，這些應用領域影響著性能標準、監管預期和數據報告要求。最後，當根據檢體類型進行分類時，樣本基質（血漿、唾液、血清、尿液、全血等）會影響檢體採集策略、分析前處理和檢測靈敏度。樣本基質的選擇將決定檢測的部署地點和方式，從中心實驗室到現場。

整合這些細分維度，可以確定哪些領域的投資和創新能帶來最大的營運效益。例如，將高靈敏度分子平台與非侵入性檢體類型相結合，將擴大社區監測的檢測覆蓋範圍；而最佳化的血清學ELISA方法在回顧性流行病學調查和疫苗反應監測中仍然至關重要。最終用戶的需求表明，沒有任何單一技術或檢體類型能夠佔據主導地位，而將技術能力與臨床和後勤環境相匹配的混合策略將推動技術的應用和影響力。

檢驗了美洲、歐洲、中東和非洲以及亞太地區在偵測能力監管和基礎設施方面的區域差異對診斷技術應用的影響。

區域趨勢對蟲媒病毒檢測的技術採納、監管路徑和部署策略有顯著影響。美洲地區的醫療保健系統多種多樣，從高通量集中式實驗室到資源有限的社區醫療機構，不一而足，因此對高通量分子平台和可靠的照護現場方案都提出了需求，以支持疫情應對和日常監測。該地區的法規結構也各不相同，一些地區強調加快緊急使用核准流程，而另一些地區則堅持嚴格的上市前證據要求，這影響了技術的採納時間和上市後義務。

歐洲、中東和非洲地區（EMEA）的基礎設施能力和公共衛生優先事項各不相同。該地區的高所得市場正日益採用先進的分子檢測方法和整合數據系統，而資源匱乏的地區則優先採用經濟高效的快速診斷方法和能夠承受惡劣現場環境的技術。跨境合作和區域公共衛生組織在協調監測方法、安排試劑購買以及協調實驗室技術人員培訓專案方面發揮著至關重要的作用。

快速的技術應用、對實驗室現代化的巨額投資以及不斷擴大的本地製造能力，共同創造了亞太地區充滿活力的環境。該地區多個國家正在擴展診斷網路，並投資於分散式檢查，以加強早期發現和疫情防治。在所有地區，公私合營和國際協作仍然是擴大診斷能力、增強供應鏈韌性和規範品質保證實踐的重要機制。

分析測試開發人員、製造商和供應專家之間的競爭策略和夥伴關係模式：推動採用和營運韌性的因素

產業相關人員正在探索一個競爭格局，在這個格局中，創新、監管合規性和分銷能力將決定其影響力和覆蓋範圍。擁有強大試劑產品組合和檢驗檢測流程的公司正致力於簡化監管申報流程並拓展分銷網路，以支援跨司法管轄區的部署。檢測開發商和儀器製造商之間的策略夥伴關係正在加速「檢體到結果」工作流程的整合，從而減少人工操作時間並最大限度地降低人為因素造成的差異。

同時，契約製造和供應專業人員在維持試劑持續供應和滿足疫情期間激增的需求方面發揮核心作用。投資於本地生產能力和品管系統的公司能夠更好地應對關稅相關的干擾，並服務於地域分散的市場。與學術機構和臨床中心建立合作關係有助於取得檢體庫和臨床檢驗途徑，對於展現實際應用效果至關重要。

最後，那些將卓越技術與強大的商業策略（靈活的定價模式、培訓和支援服務、數據分析解決方案等）相結合的公司將脫穎而出。這些能力將幫助診斷流程中的終端用戶，從需要快速整合的醫院實驗室到尋求高複雜度檢測平台的研究機構。

診斷領域的領導企業可以採取切實可行的策略步驟，以提高平台靈活性、確保供應連續性並加速資料驅動的監控能力。

產業領導者應採取一系列協調一致的行動，以加強診斷準備，加速高影響力技術的應用，並降低營運風險。首先，應優先投資於平台互通性和模組化工作流程，使實驗室能夠在密集型高通量檢測和分散式快速診斷之間靈活切換，而無需重複檢驗。這種方法可以減少營運摩擦，並最大限度地效用現有資源。

接下來，透過對關鍵試劑的多個供應來源進行資格審核、協商靈活的合約條款以應對前置作業時間波動，以及探索區域製造夥伴關係以縮短交貨週期，來規範供應鏈風險管理。將貿易合規方面的專業知識融入採購和法務部門，可以進一步最大限度地減少海關延誤，並確保供應的連續性。

第三，投資數據連接和品質保證基礎設施將實現近乎即時的報告，促進機構間數據共用，並支持監控目標的實現。培訓和人才培養同樣至關重要，旨在提升實驗室技術人員和臨床醫生在新平台上的技能的計劃，將在確保數據完整性的同時加速新平台的普及應用。最後，加強與監管機構和公共衛生機構的合作，以簡化證據產生流程，並使績效標準與公共衛生需求保持一致。這些共同努力將加強診斷系統，並提高應對突發疫情和日常監測的準備能力。

我們採用透明的多學科研究方法，結合專家直接參與、技術證據和供應鏈分析，為我們可操作的診斷見解提供支援。

本分析的調查方法融合了第一手和第二手研究、專家諮詢以及多學科檢驗，以確保其穩健性和相關性。資料來源廣泛，包括反映目前檢測效能標準和監管要求的各類科學文獻、同行評審研究、監管指導文件和技術白皮書。透過與實驗室主任、採購負責人、臨床研究人員和行業高管的訪談，我們了解了營運實踐、推廣應用促進因素和採購限制等相關背景資訊。

在適當情況下，我們整合了實驗室檢驗報告和效能評估，以比較分子、血清學和快速診斷技術的分析特性。供應鏈分析利用貿易數據、物流案例研究和採購政策審查來評估脆弱性和緩解措施。評估過程中強調了三角驗證法，並將定性訪談結果與技術文件和公共衛生報告進行交叉核對，以最大限度地減少偏差，並確保建議的可行性。

在整個研究過程中，我們注意到監管環境以及貿易和關稅政策的變化會影響診斷技術的應用。我們也指出了研究的局限性和數據缺口，並將其作為未來進行後續研究或有針對性的基礎研究的機會。

整合策略要務和合作途徑，以加強診斷系統並提高蟲媒病毒檢測應對力

總之，蟲媒病毒診斷處於技術創新、公共衛生優先事項和營運限制的策略交會點。先進的分子診斷技術、改進的快速診斷方法以及加強的數據協作，為更有效地檢測和應對蟲媒病毒威脅提供了新的機會。同時，供應鏈中斷和監管複雜性凸顯了相關人員之間周密準備和協作的必要性。

因此，決策者應採取混合診斷策略，使技術選擇與臨床和監測目標一致，促進對供應鏈韌性的投資，並優先考慮互通性和數據品質。跨部門夥伴關係對於擴大創新規模、協調標準以及確保診斷能力在不同基礎設施層級的地區之間公平分配仍然至關重要。協作行動和有針對性的投資可以加強診斷系統，並提供及時可靠的訊息，從而支持臨床護理和公共衛生干預措施。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 拓展分子診斷平台，用於快速、多重檢測登革熱、茲卡病毒、茲卡孔肯雅病毒和其他蟲媒病毒，以改善臨床決策。
  • 整合數位流行病學和基於 GIS 的監測工具，實現對蟲媒病毒疫情的即時監測和資源分配。
  • 引入照護現場核酸檢測技術，以便在資源匱乏和偏遠的流行地區進行分散式篩檢
  • 開發下一代基於 CRISPR 的生物感測器：用於靈敏的照護現場檢測蟲媒病毒感染疾病
  • 加強公私合營，加速新型黃病毒和甲病毒檢測技術的商業化。
  • 具有更高特異性的血清學檢測方法，能夠區分黃病毒感染疾病中的交叉反應抗體，正變得越來越重要。
  • 引入多重免疫檢測試劑盒以提高臨床實驗室中常見蟲媒病毒的鑑別診斷能力

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測類型分類的蟲媒病毒檢測市場

  • 分子檢測
  • 快速診斷測試
  • 血清學檢測

9. 按技術分類的蟲媒病毒檢測市場

  • ELISA
    • 競爭性ELISA
    • 間接ELISA
    • 夾心ELISA
  • 橫向流動化驗
    • 競爭性試驗
    • 夾心法
  • 微陣列
    • DNA微陣列
    • 蛋白質微陣列
  • PCR技術
    • 常規PCR
    • 數位PCR
    • 即時PCR

第10章 依最終用戶分類的蟲媒病毒檢測市場

  • 診斷實驗室
  • 醫院
  • 製藥公司
  • 研究所

第11章 依應用分類的蟲媒病毒檢測市場

  • 臨床診斷
  • 流行病學監測
  • 研究
  • 獸醫檢查

12. 依檢體類型分類的蟲媒病毒檢測市場

  • 電漿
  • 唾液
  • 血清
  • 尿
  • 全血

第13章 各地區蟲媒病毒檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 蟲媒病毒檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國蟲媒病毒檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • QIAGEN NV
    • Hologic, Inc.
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Siemens Healthineers AG
    • PerkinElmer, Inc.
Product Code: MRR-69324464D0E4

The Arbovirus Testing Market is projected to grow by USD 2.10 billion at a CAGR of 6.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.31 billion
Estimated Year [2025] USD 1.39 billion
Forecast Year [2032] USD 2.10 billion
CAGR (%) 6.02%

Framing the modern arbovirus testing environment amid shifting vector dynamics evolving clinical requirements and increasing regulatory expectations

Arboviruses continue to pose complex challenges to public health systems, diagnostic laboratories, and research organizations worldwide. Rapid global travel, shifting ecological patterns, urbanization, and climate variability are contributing to changes in vector distributions and seasonality, which in turn complicate surveillance and diagnosis. Against this backdrop, testing technologies are evolving rapidly, with molecular platforms, immunoassays, and point-of-care diagnostics each responding to distinct clinical and operational demands.

Diagnostic stakeholders are navigating an environment where speed, accuracy, and scalability must be balanced with cost and logistics. Laboratories face pressure to integrate high-throughput molecular testing with confirmatory serological assays, while clinicians require rapid triage tools to inform patient management. Research institutions and pharmaceutical companies are aligning diagnostic strategies with vaccine and therapeutics development, seeking assays that can support clinical trials and post-marketing surveillance.

In addition, regulatory expectations and quality frameworks are tightening, prompting organizations to invest in validation, quality control, and interoperability. Accordingly, strategic decisions around platform selection, sample workflows, and supply chain resilience have moved to the forefront of diagnostic planning. This introduction sets the stage for deeper analysis by highlighting the converging drivers that demand coordinated responses from technology developers, end users, and policy makers.

Navigating a rapidly evolving arbovirus diagnostics landscape propelled by technological advances digital connectivity and flexible testing workflows

The arbovirus diagnostics landscape is undergoing transformative shifts driven by technological innovation, digital integration, and operational reorientation. Molecular methods such as real-time PCR and digital PCR have advanced in sensitivity and multiplexing capability, enabling concurrent detection of multiple pathogens and reducing time to actionable results. At the same time, lateral flow formats and other rapid diagnostics have matured to offer improved sensitivity and user-friendly designs suitable for decentralized settings.

Concurrently, data integration and connectivity have become core components of diagnostic value. Laboratory information systems and cloud-enabled reporting are facilitating near real-time epidemiological surveillance and more coordinated public health responses. This digital transformation is complemented by advances in assay design, including refined antigen targets and improved monoclonal reagents, which have enhanced specificity across serological platforms.

Another notable shift is the emphasis on sample type flexibility. Performance improvements on non-invasive matrices such as saliva and urine are expanding testing options for community-based screening and pediatric populations. Supply chain considerations and cost pressures are also accelerating interest in platform consolidation and modular workflows that can pivot between high-throughput centralized testing and point-of-care deployment. Taken together, these shifts are reshaping how stakeholders conceive of diagnostics as part of integrated health system responses.

Assessing the cumulative repercussions of 2025 tariff adjustments on arbovirus diagnostic supply chains procurement strategies and operational continuity

Trade policies and tariff adjustments have introduced new considerations for sourcing reagents, instruments, and consumables used in arbovirus testing. Tariff changes in 2025 created immediate procurement complexities that required organizations to reassess supplier contracts, inventory strategies, and cross-border logistics to preserve continuity of testing operations. The added import costs on certain assay components and instruments contributed to a renewed focus on supply chain localization and dual-sourcing arrangements.

In response, many laboratories and manufacturers intensified efforts to qualify alternative suppliers and to evaluate the feasibility of regional manufacturing partnerships. These moves were often accompanied by reconfigured purchasing timelines to build buffer stocks for critical reagents while avoiding obsolescence for items with limited shelf life. Procurement teams increasingly incorporated tariff risk assessments into vendor selection and contractual terms, negotiating price protection clauses and flexible delivery schedules.

Moreover, regulatory and customs clearance processes in affected jurisdictions required closer engagement with trade compliance specialists to expedite import approvals for essential diagnostic materials. For organizations involved in multinational clinical programs, these tariff shifts also prompted closer coordination with sponsors to ensure study continuity and to preempt delays in reagent availability. Ultimately, the cumulative impact of the 2025 tariffs accelerated strategic shifts toward supply chain resilience and closer collaboration between procurement, laboratory operations, and regulatory affairs.

Uncovering high-value intersections across test types technologies end users applications and sample types that drive diagnostic relevance and strategic prioritization

Segmentation analysis reveals nuanced performance and adoption patterns across test types, technologies, end users, applications, and sample matrices, providing a multi-dimensional view of diagnostic requirements and opportunities. Based on Test Type, the landscape differentiates between molecular tests, rapid diagnostic tests, and serological tests, each serving discrete clinical and surveillance functions and requiring distinct validation pathways and operational workflows. Based on Technology, assay development and deployment are informed by choices among ELISA, lateral flow assays, microarray platforms, and PCR technologies; within ELISA, competitive, indirect, and sandwich formats present trade-offs in sensitivity and cross-reactivity, while lateral flow designs-competitive assay and sandwich assay-deliver varying performance characteristics for point-of-care use. The microarray domain encompasses both DNA microarray and protein microarray approaches that support high-content screening and pathogen discovery, and PCR technology includes conventional PCR, digital PCR, and real-time PCR, each enabling different analytical resolutions and throughput profiles. Based on End User, diagnostic needs and procurement behaviors differ across diagnostic laboratories, hospitals, pharmaceutical companies, and research institutions, with laboratories prioritizing throughput and quality management, hospitals emphasizing clinical turnaround and ease of use, pharmaceutical companies requiring assay standardization for trials, and research institutions focusing on innovation and exploratory capacity. Based on Application, testing is deployed across clinical diagnostics, epidemiological surveillance, research, and veterinary testing, which shape performance criteria, regulatory expectations, and data reporting requirements. Finally, based on Sample Type, matrices such as plasma, saliva, serum, urine, and whole blood influence specimen collection strategies, pre-analytical handling, and assay sensitivity; the choice of matrix often governs where and how tests are deployed, from centralized labs to field settings.

Integrating these segmentation dimensions suggests where investments and innovations can yield the greatest operational benefits. For example, combining high-sensitivity molecular platforms with non-invasive sample types expands testing reach for community surveillance, whereas optimized serological ELISA formats remain critical for retrospective epidemiology and vaccine response monitoring. End-user needs underscore that no single technology or sample type will dominate; instead, hybrid strategies that match technology capabilities to clinical and logistical contexts will drive adoption and impact.

Examining how regional diversity in capacity regulation and infrastructure among the Americas Europe Middle East & Africa and Asia-Pacific shapes diagnostic deployment

Regional dynamics exert strong influence over technology adoption, regulatory pathways, and deployment strategies for arbovirus testing. In the Americas, health systems vary from high-capacity centralized laboratories to resource-constrained community settings, generating demand for both high-throughput molecular platforms and robust point-of-care solutions that can support outbreak response and routine surveillance. Regulatory frameworks in the region also vary, with some jurisdictions emphasizing rapid emergency use pathways and others maintaining stringent premarket evidence requirements, which affects time to implementation and post-market obligations.

Across Europe, Middle East & Africa, the landscape is characterized by heterogeneity in infrastructural capacity and public health priorities. High-income markets within this region tend to adopt advanced molecular assays and integrated data systems, whereas lower-resource areas prioritize cost-effective rapid diagnostics and technologies that tolerate challenging field conditions. Cross-border cooperation and regional public health bodies play pivotal roles in harmonizing surveillance approaches, facilitating reagent procurement, and coordinating training programs for laboratory personnel.

In Asia-Pacific, rapid technological uptake, significant investments in laboratory modernization, and growing local manufacturing capabilities are shaping a dynamic environment. Several countries in the region are expanding diagnostic networks and investing in decentralized testing to strengthen early detection and outbreak containment. Across all regions, public-private partnerships and international collaborations remain key mechanisms for scaling diagnostic capacity, enhancing supply chain resilience, and standardizing quality assurance practices.

Profiling competitive approaches and partnership models among assay developers manufacturers and supply specialists that drive adoption and operational resilience

Industry participants are navigating a competitive landscape where innovation, regulatory alignment, and distribution capabilities determine influence and reach. Companies with strong reagent portfolios and validated assay pipelines are focusing on streamlining regulatory filings and expanding distribution networks to support multi-jurisdictional deployments. Strategic partnerships between assay developers and instrument manufacturers are accelerating integration of sample-to-answer workflows that reduce hands-on time and minimize user-dependent variability.

At the same time, contract manufacturing and supply specialists are becoming central to maintaining reagent continuity and meeting surge demand during outbreak periods. Firms that invest in local manufacturing capacity and quality management systems are better positioned to respond to tariff-related disruptions and to serve regionally diverse markets. Collaborations with academic and clinical centers facilitate access to specimen panels and clinical validation pathways, which are essential for demonstrating real-world performance.

Finally, companies that combine technical excellence with robust commercial strategies-such as flexible pricing models, training and support services, and data analytics offerings-are differentiating themselves. These capabilities support end users across the diagnostic continuum, from hospital laboratories requiring rapid integration to research institutions seeking high-complexity assay platforms.

Actionable strategic measures for diagnostic leaders to enhance platform flexibility ensure supply continuity and accelerate data driven surveillance capabilities

Industry leaders should pursue a coordinated set of actions to strengthen diagnostic readiness, accelerate adoption of high-impact technologies, and mitigate operational risks. First, prioritize investments in platform interoperability and modular workflows that enable laboratories to pivot between centralized high-throughput testing and decentralized rapid diagnostics without duplicative validation burdens. This approach reduces operational friction and maximizes the utility of existing capital equipment.

Second, formalize supply chain risk management by qualifying multiple sources for critical reagents, negotiating flexible contractual terms to buffer against tariff fluctuations, and exploring regional manufacturing partnerships to shorten lead times. Embedding trade compliance expertise within procurement and legal teams will further minimize customs delays and ensure continuity of supply.

Third, invest in data connectivity and quality assurance infrastructure to enable near real-time reporting, facilitate cross-institutional data sharing, and support surveillance objectives. Training and workforce development are equally essential; targeted programs that upskill laboratory technicians and clinicians in new platforms will accelerate adoption while preserving data integrity. Finally, foster collaborations with regulators and public health agencies to streamline evidence generation and to align performance criteria with public health needs. These combined actions will strengthen diagnostic systems and improve readiness for episodic outbreaks and routine surveillance alike.

Transparent multidisciplinary research approach combining primary expert engagement technical evidence and supply chain analysis to underpin actionable diagnostic insights

The research methodology underpinning this analysis combines primary and secondary evidence, expert consultations, and cross-disciplinary validation to ensure robustness and relevance. Data inputs were collected from a wide range of scientific literature, peer-reviewed studies, regulatory guidance documents, and technical white papers that reflect current assay performance standards and regulatory expectations. Primary interviews with laboratory directors, procurement leads, clinical researchers, and industry executives provided context on operational practices, adoption drivers, and procurement constraints.

Where appropriate, laboratory validation reports and performance evaluations were synthesized to compare analytical characteristics of molecular, serological, and rapid diagnostic technologies. Supply chain analyses drew on trade data, logistics case studies, and procurement policy reviews to assess vulnerabilities and mitigation strategies. The assessment process emphasized triangulation: findings from qualitative interviews were cross-checked against technical documentation and public health reports to minimize bias and to ensure that recommendations are operationally actionable.

Throughout the research, attention was paid to regulatory landscapes and to documented changes in trade and customs policies that influence diagnostic deployment. Limitations and data gaps were identified and flagged for potential follow-up research or targeted primary studies.

Synthesis of strategic imperatives and collaborative pathways to strengthen diagnostic systems and improve arbovirus detection responsiveness

In conclusion, arbovirus diagnostics sit at a strategic intersection of technological innovation, public health priorities, and operational constraints. The convergence of advanced molecular methods, improved rapid diagnostics, and enhanced data connectivity provides new opportunities to detect and respond to arboviral threats more effectively. At the same time, supply chain disruptions and regulatory complexities underscore the need for deliberate planning and cooperative approaches across stakeholders.

Decision-makers should therefore adopt hybrid diagnostic strategies that align technology choice with clinical and surveillance objectives, invest in supply chain resilience, and prioritize interoperability and data quality. Cross-sector partnerships will remain essential to scale innovations, harmonize standards, and ensure that diagnostic capacity is equitably distributed across regions with differing infrastructural capabilities. With coordinated action and targeted investments, diagnostic systems can be strengthened to deliver timely, reliable insights that support clinical care and public health interventions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding molecular diagnostic platforms for rapid multiplex detection of dengue, Zika, chikungunya and other arboviruses to improve clinical decision-making
  • 5.2. Integration of digital epidemiology and GIS-based surveillance tools for real-time arbovirus outbreak monitoring and resource allocation
  • 5.3. Adoption of point-of-care nucleic acid tests enabling decentralised screening in low-resource and remote endemic regions
  • 5.4. Development of next-generation CRISPR-based biosensors for high-sensitivity point-of-care detection of arbovirus infections
  • 5.5. Increasing public-private partnerships to accelerate the commercialization of novel flavivirus and alphavirus testing technologies
  • 5.6. Growing emphasis on serological assays with improved specificity to differentiate cross-reactive antibodies among flavivirus infections
  • 5.7. Implementation of multiplex immunoassay panels that improve differential diagnosis of co-circulating arboviruses in clinical laboratories

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Arbovirus Testing Market, by Test Type

  • 8.1. Molecular Tests
  • 8.2. Rapid Diagnostic Tests
  • 8.3. Serological Tests

9. Arbovirus Testing Market, by Technology

  • 9.1. ELISA
    • 9.1.1. Competitive ELISA
    • 9.1.2. Indirect ELISA
    • 9.1.3. Sandwich ELISA
  • 9.2. Lateral Flow Assays
    • 9.2.1. Competitive Assay
    • 9.2.2. Sandwich Assay
  • 9.3. Microarray
    • 9.3.1. DNA Microarray
    • 9.3.2. Protein Microarray
  • 9.4. PCR Technology
    • 9.4.1. Conventional PCR
    • 9.4.2. Digital PCR
    • 9.4.3. Real-Time PCR

10. Arbovirus Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Pharmaceutical Companies
  • 10.4. Research Institutions

11. Arbovirus Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Epidemiological Surveillance
  • 11.3. Research
  • 11.4. Veterinary Testing

12. Arbovirus Testing Market, by Sample Type

  • 12.1. Plasma
  • 12.2. Saliva
  • 12.3. Serum
  • 12.4. Urine
  • 12.5. Whole Blood

13. Arbovirus Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Arbovirus Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Arbovirus Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. bioMerieux SA
    • 16.3.5. QIAGEN N.V.
    • 16.3.6. Hologic, Inc.
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Danaher Corporation
    • 16.3.9. Siemens Healthineers AG
    • 16.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ARBOVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ARBOVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARBOVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARBOVIRUS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY COMPETITIVE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SANDWICH ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DNA MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PROTEIN MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY VETERINARY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ARBOVIRUS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY PCR TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST ARBOVIRUS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA ARBOVIRUS TESTING MARKET SIZE, BY LATERA